Eye drug firm Akorn to buy rival Hi-Tech Pharmacal for $640 mln
Aug 27 (Reuters) - Specialty pharmaceutical company Akorn Inc will buy rival Hi-Tech Pharmacal Co Inc for $640 million in cash to expand its eye drug portfolio to other dosage forms such as oral liquids, topical creams and ointments.
Akorn will pay $43.50 per Hi-Tech share, representing a premium of 23.5 percent to Hi-Tech's last close.
The deal will make Akorn the third-largest U.S. generic ophthalmic player and will significantly increase its retail presence in both prescription and over-the-counter products, the companies said in a statement.
- Scores possibly exposed to U.S. Ebola patient; four isolated |
- Islamic State committing 'staggering' crimes in Iraq: U.N. report
- Scores possibly exposed to U.S. Ebola patient; four isolated
- Hong Kong police warn protesters against occupying buildings |
- Israel's Netanyahu to Obama: Don't allow Iran deal that leaves it at nuclear threshold